P36. Validação Do Algoritmo Frax Para a População Portuguesa

Marques, Andréa; Mota, António; Canhão, Helena; Romeu, José Carlos; Machado, Pedro; Silva, Daiany de Mendonça; Ruano, Afonso; Barbosa, Ana Paula; Dias, A. Aroso; Araújo, Domingos; Simões, E.; Águas, Fernanda; Silva, Inês; SILVA, IDSON EMANUEL CAVALCANTI; Crespo, Jorge; Alves, José Delgado; Costa, Lúcia; Mascarenhas, Mário Rui; Lourenço, Óscar; Ferreira, Pedro Lopes; Lucas, Raquel; Roque, Rafael; Branco, Jaime; Tavares, Viviana; Kanis, JA; Silva, J.A.P. da

doi:10.1016/s1646-3439(12)70162-1

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence and costs of hip fractures were taken from Marques et al [11,13]. As vertebral, forearm and other fractures are inconsistently reported in Portugal [11,18], the incidence and cost of clinical vertebral fractures, forearm and other fractures was calculated by assuming that the ratio of these fractures to hip fracture would be similar in Portugal as compared to Sweden [15,19] ( Table 2).…”

Section: Incidence Mortality and Costs Of Fractures According To Agementioning

confidence: 99%

“…As vertebral, forearm and other fractures are inconsistently reported in Portugal [11,18], the incidence and cost of clinical vertebral fractures, forearm and other fractures was calculated by assuming that the ratio of these fractures to hip fracture would be similar in Portugal as compared to Sweden [15,19] ( Table 2). A similar methodology has been adopted in other published studies [9,11,20].…”

Section: Incidence Mortality and Costs Of Fractures According To Agementioning

confidence: 99%

“…The effects of vertebral, forearm and other fractures on QoL were based on Swedish data [29,30] as no reliable data are available for Portugal. A similar methodology has been adopted in other published studies [9,11,20]. The multipliers to convey the impact of fractures on QoF are presented in Table 1.…”

Section: Utilitiesmentioning

confidence: 99%

“…This strategy has already been adopted in the UK [7], US [8], Switzerland [9] and Greece [10]. FRAX Ò has been calibrated to the Portuguese epidemiological context and made available-FRAX Ò Port [11]. Recent national studies proving population reference values for QoL [12] and data on the impact of hip fractures in terms of costs, QoL and mortality [13] have laid the ground to promote this important development in Portugal.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal

et al. 2016

View full text Add to dashboard Cite

Cost-effective intervention thresholds (ITs) based on FRAX(®) were determined for Portugal. Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8.8 and 2.5 %, respectively. The aim of the present study was to identify the 10-year probabilities of a major and hip osteoporotic fracture using FRAX(®) validated for Portugal, above which pharmacologic interventions become cost effective in the Portuguese context. A previously developed and validated state transition Markov cohort model was populated with epidemiologic, economic and quality-of-life fracture data from Portugal. Cost-effectiveness of FRAX(®)-based ITs was calculated for generic alendronate and proprietary zoledronic acid, denosumab and teriparatide were compared to "no intervention", assuming a WTP of €32,000 (two times national Gross Domestic Product per capita) per QALYs. In the Portuguese epidemiological and economic context, treatment with generic alendronate was cost effective for men and women aged 50 years or more, with 10-year probabilities at or above 8.8 % for major osteoporotic fractures and 2.5 % for hip fractures. Cost-effective threshold 10-year probabilities for major osteoporotic and hip fractures were higher for zoledronic acid (20.4 and 10.1 %), denosumab (34.9 and 10.1 %) and teriparatide (77.8 and 62.6 %), respectively. A tool is provided to perform the calculation of cost-effective ITs for different medications, according to age group and diverse levels of WTP. Cost-effective ITs, for different medications, age groups and WTP, based on 10-year probabilities of major and hip fracture probabilities calculated with FRAX are provided.

show abstract